Clinical characteristics of the women at baseline and the characteristics at follow-up
| . | Control group . | APS group . | P . |
|---|---|---|---|
| N | 796 | 517 | |
| Age, y | 30 (5) [17-44] | 29 (4) [16-41] | .19 |
| >35 y, n (%) | 43 (5.4%) | 15 (2.9%) | .031 |
| BMI, kg/m2 | 25.6 (4.5) [15.3-36.1] | 26.0 (4.6) [15.3-37.0] | .18 |
| >30 kg/m2 | 78 (9.8%) | 60 (11.6%) | .30 |
| <18.5 kg/m2 | 12 (1.5%) | 5 (1%) | .55 |
| Ethnicity | .92 | ||
| White | 753 (94.6%) | 489 (94.6%) | |
| From Europe | 647 (81.3%) | 420 (81.2%) | |
| From North Africa | 106 (13.3%) | 69 (13.4%) | |
| Black Africans | 36 (4.5%) | 22 (4.2%) | |
| Asians | 7 (0.9%) | 6 (1.2%) | |
| PL subtypes | |||
| Embryonic PL <10 WG | 483 (60.7%) | 206 (39.8%) | <.0001 |
| Fetal PL >10 WG | 313 (39.3%) | 311 (60.2%) | |
| Primary PL | 549 (68.9%) | 342 (66.1%) | .29 |
| Secondary PL | 247 (31.1%) | 175 (33.9%) | |
| Inflammatory disease | 7 (0.9%) | 32 (6.2%) | <.0001 |
| Current tobacco users | 83 (10.4%) | 50 (9.7%) | .66 |
| Hypertension | 19 (2.4%) | 17 (3.3%) | .33 |
| Positive history in a first-degree relative | |||
| Venous thromboembolism | 15 (1.9%) | 12 (2.3%) | .59 |
| Atherothrombosis | 96 (12.1%) | 53 (10.3%) | .31 |
| Recurrent abortion | 49 (6.2%) | 14 (2.7%) | .004 |
| Fetal loss | 33 (4.1%) | 6 (1.2%) | .003 |
| Hyperlipidemia | |||
| Hypercholesterolemia | 42 (5.3%) | 31 (6.0%) | .58 |
| Hypertriglyceridemia | 34 (4.3%) | 27 (5.2%) | .42 |
| New pregnancy during the 18-mo observational period | 791 (99.4%) | 513 (99.2%) | .98 |
| Interval between the inclusion and the new pregnancy, days | 156 (29) [95-386] | 143 (33) [91-378] | .32 |
| Length of time between stopping LMWH/LDA treatment and pregnancy related procedures, number of complete hours | NA | 14 (3) [7-29] |
| . | Control group . | APS group . | P . |
|---|---|---|---|
| N | 796 | 517 | |
| Age, y | 30 (5) [17-44] | 29 (4) [16-41] | .19 |
| >35 y, n (%) | 43 (5.4%) | 15 (2.9%) | .031 |
| BMI, kg/m2 | 25.6 (4.5) [15.3-36.1] | 26.0 (4.6) [15.3-37.0] | .18 |
| >30 kg/m2 | 78 (9.8%) | 60 (11.6%) | .30 |
| <18.5 kg/m2 | 12 (1.5%) | 5 (1%) | .55 |
| Ethnicity | .92 | ||
| White | 753 (94.6%) | 489 (94.6%) | |
| From Europe | 647 (81.3%) | 420 (81.2%) | |
| From North Africa | 106 (13.3%) | 69 (13.4%) | |
| Black Africans | 36 (4.5%) | 22 (4.2%) | |
| Asians | 7 (0.9%) | 6 (1.2%) | |
| PL subtypes | |||
| Embryonic PL <10 WG | 483 (60.7%) | 206 (39.8%) | <.0001 |
| Fetal PL >10 WG | 313 (39.3%) | 311 (60.2%) | |
| Primary PL | 549 (68.9%) | 342 (66.1%) | .29 |
| Secondary PL | 247 (31.1%) | 175 (33.9%) | |
| Inflammatory disease | 7 (0.9%) | 32 (6.2%) | <.0001 |
| Current tobacco users | 83 (10.4%) | 50 (9.7%) | .66 |
| Hypertension | 19 (2.4%) | 17 (3.3%) | .33 |
| Positive history in a first-degree relative | |||
| Venous thromboembolism | 15 (1.9%) | 12 (2.3%) | .59 |
| Atherothrombosis | 96 (12.1%) | 53 (10.3%) | .31 |
| Recurrent abortion | 49 (6.2%) | 14 (2.7%) | .004 |
| Fetal loss | 33 (4.1%) | 6 (1.2%) | .003 |
| Hyperlipidemia | |||
| Hypercholesterolemia | 42 (5.3%) | 31 (6.0%) | .58 |
| Hypertriglyceridemia | 34 (4.3%) | 27 (5.2%) | .42 |
| New pregnancy during the 18-mo observational period | 791 (99.4%) | 513 (99.2%) | .98 |
| Interval between the inclusion and the new pregnancy, days | 156 (29) [95-386] | 143 (33) [91-378] | .32 |
| Length of time between stopping LMWH/LDA treatment and pregnancy related procedures, number of complete hours | NA | 14 (3) [7-29] |
The control group comprised women with negative thrombophilia screening results. The APS group comprised women positive for antiphospholipid antibodies. Quantitative data are given as medians (interquartile range) [range] and qualitative data as numbers (percentages).
NA, not applicable; PL, pregnancy loss.